Literature DB >> 9044476

Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung.

S Iwabuchi1, S Ono, T Tanita, K Koike, S Fujimura.   

Abstract

Vasoactive intestinal peptide (VIP) is one of the chief neurotransmitters of nonadrenergic noncholinergic nerve fibers. In this study, we investigated the effect of VIP on the pulmonary circulation in isolated perfused rat lungs. Baseline pressures of the pulmonary artery for the isolated rat lungs were not affected by 3 x 10(-8) M VIP. VIP caused dose-dependent pulmonary vasodilation when the pulmonary vascular bed was constricted with 20 mM KCl. This vasodilative effect of VIP was inhibited by 1 x 10(-6) M L-n omega-nitro-arginine, an endothelium-derived relaxing factor (nitric oxide) inhibitor, and was restored by the addition of 10(-4) M L-arginine, a substrate of nitric oxide. VIP also caused suppression of the ANG II pressor response, and this VIP-induced suppressive effect was reduced when L-N omega-nitro-arginine or 3 x 10(-6) M meclofenamate was added to the perfusate. These results indicate that VIP causes pulmonary vasodilation in isolated rat lung and suggest the possible involvement of NO and/or cyclooxygenase metabolites in VIP-induced pulmonary vasodilation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044476     DOI: 10.1159/000196643

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  4 in total

1.  Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms.

Authors:  Shuang Zhang; Yun Liu; Shouli Guo; Jianing Zhang; Xiaojie Chu; Chun Jiang; Daling Zhu
Journal:  J Physiol Sci       Date:  2010-08-07       Impact factor: 2.781

2.  Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

Authors:  Ventzislav Petkov; Wilhelm Mosgoeller; Rolf Ziesche; Markus Raderer; Leopold Stiebellehner; Karin Vonbank; Georg-Christian Funk; Gerhard Hamilton; Clemens Novotny; Bernhard Burian; Lutz-Henning Block
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 3.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

4.  Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension.

Authors:  Walid Habre; Gergely Albu; Tibor Z Janosi; Fabienne Fontao; Britta S von Ungern-Sternberg; Maurice Beghetti; Ferenc Petak
Journal:  Respir Res       Date:  2011-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.